Genmab A (GMAB) Cash & Equivalents Growth (3y) (2021 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Cash & Equivalents Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -25.80% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -17.71% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -15.41% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 8.23% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -23.18% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 47.78% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 37.45% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -21.12% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 13.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.27% |
| Mar 31, 2026 | 8.89% |
| Dec 31, 2025 | 6.52% |
| Sep 30, 2025 | -28.03% |
| Jun 30, 2025 | 9.00% |
| Mar 31, 2025 | 18.52% |
| Dec 31, 2024 | -2.59% |
| Sep 30, 2024 | -15.53% |
| Jun 30, 2024 | -17.93% |
| Mar 31, 2024 | -43.63% |
| Dec 31, 2023 | 19.01% |
| Sep 30, 2023 | -47.03% |
| Jun 30, 2023 | 14.89% |
| Jan 1, 2023 | 60.93% |
| Dec 31, 2022 | 34.26% |
| Sep 30, 2022 | -55.40% |
| Jun 30, 2022 | 153.04% |
| Dec 31, 2021 | 156.32% |
| Jun 30, 2021 | 107.71% |